S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:NVCNNeovasc Stock Price, Forecast & News

$2.17
-0.02 (-0.91 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.08
Now: $2.17
$2.24
50-Day Range
$2.27
MA: $2.47
$2.80
52-Week Range
$1.24
Now: $2.17
$8.65
Volume262,635 shs
Average Volume349,708 shs
Market Capitalization$24.16 million
P/E RatioN/A
Dividend YieldN/A
Beta2.76
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Read More
Neovasc logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCN
CUSIPN/A
Phone604-248-4138

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.09 million
Book Value($1.46) per share

Profitability

Net Income$-35,130,000.00
Net Margins-1,729.99%

Miscellaneous

Employees98
Market Cap$24.16 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$2.17
-0.02 (-0.91 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neovasc (NASDAQ:NVCN) Frequently Asked Questions

How has Neovasc's stock price been impacted by COVID-19 (Coronavirus)?

Neovasc's stock was trading at $2.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVCN stock has decreased by 1.8% and is now trading at $2.17.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Neovasc?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neovasc
.

When is Neovasc's next earnings date?

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Neovasc
.

How were Neovasc's earnings last quarter?

Neovasc Inc (NASDAQ:NVCN) released its quarterly earnings results on Thursday, August, 6th. The medical equipment provider reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.22.
View Neovasc's earnings history
.

When did Neovasc's stock split? How did Neovasc's stock split work?

Neovasc shares reverse split before market open on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

What guidance has Neovasc issued on next quarter's earnings?

Neovasc issued an update on its second quarter 2020 IntraDay earnings guidance on Monday, July, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $295K - 295K.

What price target have analysts set for NVCN?

3 equities research analysts have issued 1 year price targets for Neovasc's stock. Their forecasts range from $3.00 to $15.00. On average, they anticipate Neovasc's stock price to reach $7.67 in the next year. This suggests a possible upside of 253.3% from the stock's current price.
View analysts' price targets for Neovasc
.

Has Neovasc been receiving favorable news coverage?

Press coverage about NVCN stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neovasc earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Neovasc
.

Are investors shorting Neovasc?

Neovasc saw a drop in short interest in June. As of June 30th, there was short interest totaling 185,500 shares, a drop of 13.1% from the June 15th total of 213,500 shares. Based on an average daily trading volume, of 376,800 shares, the short-interest ratio is presently 0.5 days. Approximately 1.4% of the company's stock are sold short.
View Neovasc's Short Interest
.

Who are some of Neovasc's key competitors?

What other stocks do shareholders of Neovasc own?

Who are Neovasc's key executives?

Neovasc's management team includes the following people:
  • Mr. Fredericus A. Colen, Pres & CEO (Age 66)
  • Mr. Christopher Clark B.A., C.A., BA (Honours), PgD, CA, CFO & Corp. Sec. (Age 47)

What is Neovasc's stock symbol?

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Who are Neovasc's major shareholders?

Neovasc's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hudson Bay Capital Management LP (5.68%), Sabby Management LLC (2.93%), Wedbush Securities Inc. (0.40%) and Bank of America Corp DE (0.18%).

Which institutional investors are buying Neovasc stock?

NVCN stock was acquired by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Sabby Management LLC, Wedbush Securities Inc., and Bank of America Corp DE.

How do I buy shares of Neovasc?

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neovasc's stock price today?

One share of NVCN stock can currently be purchased for approximately $2.17.

How big of a company is Neovasc?

Neovasc has a market capitalization of $24.16 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

What is Neovasc's official website?

The official website for Neovasc is www.neovasc.com.

How can I contact Neovasc?

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.